- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Columbia University Medical Center | Strategic Alliance Partners
At the Herbert Irving Comprehensive Cancer Center at Columbia University and NewYork-Presbyterian Hospital, we believe that our discoveries here will end cancer everywhere.
Working together, we empower innovation and discovery in prevention, research and clinical care to reduce the burden of cancer for our patients, our community, and the world.
Latest from Columbia University Medical Center
Dr. Rizvi on Biomarkers of Response to Immunotherapy in NSCLC
January 04, 2021
Video
Naiyer A. Rizvi, MD, discusses the use of biomarkers to select patients with non–small cell lung cancer for treatment with immunotherapy.
Dr. Rizvi on the Rationale to Evaluate Telaglenastat in KEAP1/NRF2-Mutant NSCLC
November 18, 2020
Video
Naiyer A. Rizvi, MD, discusses the rationale to evaluate the investigational glutaminase inhibitor telaglenastat in patients with non–small cell lung cancer who harbor KEAP1 or NRF2 mutations.
Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas
October 22, 2020
Video
Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.
Investigators Tackle New NSCLC Target With Glutaminase Inhibitor
October 19, 2020
Article
Telaglenastat, a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types.
Dr. Schwartz on Future Research Efforts in Sarcoma
October 15, 2020
Video
Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.
Preclinical Data Suggest Novel Molecule Enhances Immunotherapy Response in CRC
September 17, 2020
Article
Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.